Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209497 | 0.81 | ATM (0.43) | MAPTALDH1A1ATML3MBTL1PKM | |
| SCHEMBL812203 | 0.80 | ATM (0.41) | MAPTTP53TAS1R3TAS1R1KDM4E | |
| SCHEMBL14382020 | 0.78 | ATM (0.42) | MAPTTAS1R3TAS1R1KDM4EALDH1A1 | |
| SCHEMBL6928309 | 0.74 | ALDH1A1 (0.49) | MAPTTP53TAS1R3TAS1R1KDM4E | |
| SCHEMBL11217062 | 0.71 | ALDH1A1 (0.39) | MAPTKDM4EALDH1A1ATMPKM | |
| SCHEMBL20924718 | 0.70 | TSHR (0.52) | MAPTALDH1A1L3MBTL1POLBPKM | |
| SCHEMBL8022828 | 0.70 | TP53 (0.39) | TP53TAS1R3TAS1R1KDM4EPOLB | |
| SCHEMBL2687043 | 0.69 | TAS1R3 (0.36) | TP53TAS1R3TAS1R1KDM4EALDH1A1 | |
| SCHEMBL1476733 | 0.68 | ALDH1A1 (0.36) | TP53TAS1R3TAS1R1KDM4EALDH1A1 | |
| SCHEMBL1814587 | 0.68 | TAS1R3 (0.52) | TAS1R3TAS1R1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030096806-A1 | Arylphenyl-substituted cyclic ketoenols | LIEB FOLKER (DE) | 2003-05-22 | — | — | US | disclosed |
| US-6451843-B1 | Arylphenyl-substituted cyclic keto enols | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-1075465-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO ENOLS | BAYER AG (DE) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999055673-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO ENOLS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096806-A1 | Arylphenyl-substituted cyclic ketoenols | KCNE1, KCNQ3, SULT1E1 | MAPT 4861/4885TP53 3579/4885TAS1R3 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.